Page last updated: 2024-11-07

n-acetyltalosaminuronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetyltalosaminuronic acid: partially comprises saccharide frame of pseudomurein; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetyl-alpha-L-talosaminuronic acid : A carbohydrate acid derivative that is alpha-L-talosaminuronic acid in which the hydroxy group at position 2 is substituted by an acetamido group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID146155
CHEBI ID85106
MeSH IDM0123469

Synonyms (16)

Synonym
talanac
n-acetyltalosaminuronic acid
(2r,3s,4s,5r,6r)-5-acetamido-3,4,6-trihydroxyoxane-2-carboxylic acid
v3wf9vu8ds ,
alpha-l-n-acetyltalosaminuronic acid
90319-06-5
unii-v3wf9vu8ds
alpha-l-talopyranuronic acid, 2-(acetylamino)-2-deoxy-, (5z,11alpha,13e,15s)-
alpha-l-2-n-acetylamino-2-desoxytaluronic acid
2-acetamido-2-deoxy-alpha-l-talopyranuronic acid
n-acetyl-alpha-l-talosaminuronic acid
CHEBI:85106
DTXSID70238090
Q6951349
2-(acetylamino)-2-deoxy-.alpha.-l-talopyranuronic acid
.alpha.-l-talopyranuronic acid, 2-(acetylamino)-2-deoxy-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Extended interval dosing (EID) of Natalizumab (NAT) has been proposed to reduce progressive multifocal leukoencephalopathy (PML) risk associated with standard interval dosing (SID) in people with multiple sclerosis (MS)."( sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
Bava, CI; Bertolotto, A; Capobianco, MA; Malucchi, S; Martire, S; Valentino, P, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
carbohydrate acid derivativeA carbohydrate derivative that is formally obtained from a carbohydrate acid.
amino monosaccharideAny amino sugar that is a monosaccharide in which one alcoholic hydroxy group is replaced by an amino group.
hexuronic acid derivativeA uronic acid derivative that is a derivative of any hexuronic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's1 (5.88)18.2507
2000's1 (5.88)29.6817
2010's4 (23.53)24.3611
2020's7 (41.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.83 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.05 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]